Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to investigate cancer treatment technologies.
Shanghai Cell Therapy Group has partnered with a researcher from the University of Southern California (USC) to develop a way to culture hematopoietic stem and progenitor cells outside of the body.
A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University of Notre Dame Center for Research Computing.
A supplier of active pharmaceutical ingredients, CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273.
MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership will help accelerate the vaccine candidates to phase I clinical trials.
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19.
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity and more.
Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.
Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2.